Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $215.00 at Citigroup

Krystal Biotech (NASDAQ:KRYS) had its price objective boosted by Citigroup from $206.00 to $215.00 in a research report released on Thursday,Benzinga reports. Citigroup currently has a neutral rating on the stock.

Several other brokerages have also issued reports on KRYS. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday. Chardan Capital lifted their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $182.62 on Thursday. The firm has a market capitalization of $5.25 billion, a price-to-earnings ratio of 61.08 and a beta of 0.84. The business has a 50 day simple moving average of $157.18 and a 200-day simple moving average of $175.18. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.30 EPS. As a group, analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after buying an additional 21,133 shares during the period. Vanguard Group Inc. grew its position in Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after acquiring an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC grew its position in Krystal Biotech by 0.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after acquiring an additional 6,600 shares in the last quarter. State Street Corp increased its stake in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after purchasing an additional 11,411 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).